In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi ...

Special assistant to Prime Minister on Health Dr Zafar Mirza says federal government had planned to introduce auto-disable syringes next year for reducing ... to play their role in educating the ...

The Vyvgart Hytrulo prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc), co-formulated with Halozyme’s ENHANZE drug delivery technology, has been approved as a 20-to-30-second subcutaneous ...

The higher doses of the drug are yet to be launched in India (as of April 2025), and currently, it is available only in vial form rather than a prefilled syringe, making it inconvenient to administer.

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver. Vyvgart Hytrulo should be injected into a pinched skin area on the ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional. The approval is based on studies ...

(NBC News) The FDA approved a prefilled syringe formulation of efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo) for people with anti-acetylcholine receptor antibody-positive generalized ...

Yuflyma is available as a 20 mg, 40 mg and 80 mg solution for injection in both a prefilled syringe and autoinjector pen.

The high-concentration form of YUFLYMA was FDA-approved in May 2023 and is currently available as 20mg, 40 mg and 80mg solution for injection in a prefilled syringe and in an autoinjector pen. YUFLYMA ...